Last Updated on December 31, 2023 by The Health Master
A total of 20 projects under the production linked incentive (PLI) scheme for bulk drugs, conceived by the Central government to support Indian pharma attaining self sufficiency on bulk drug production, with an investment of around Rs. 840 crore is expected to achieve commercial production by March 31, 2022.
Out of the 49 projects approved so far under PLI scheme for bulk drugs, 8 projects with investment of Rs. 335 crore and with an annual production capacity of 16,021 MT have been commissioned as on date.
Further, 12 projects with committed investment of Rs. 504 crore and having annual production capacity of 18,614 MT are in the advanced stage of completion for commercial production and expected to be completed by March 31, 2022, said the ministry of chemicals and fertilisers.
The bulk drug plants that have already been commissioned include CDA, Para amino phenol, atorvastatin, sulfadizine, oxcarbazepine, levofloxacin , carbidopa and levodopa with total capacity of over 16000 MT and an investment of Rs. 335 crore.
Government of India announced the PLI scheme for bulk drugs in March 2020 to attain self-reliance in the sector of identified critical drugs.
The notification and Scheme Guidelines were issued on 27th July 2020. Total 49 projects have been approved for 33 critical APIs with a committed investment of Rs. 3,685 crore.
The Union minister for chemical and fertilizers Dr Mansukh Mandaviya, interacted with the company representatives of bulk drugs PLI scheme beneficiaries virtually on February 25. minister of state Shri Bhagwant Khuba was also present on the occasion.
During the meeting, all the representatives of these 20 projects presented their efforts in grounding and commissioning the projects despite the C-19 pandemic and appreciated the support given by the government for handholding and trying to resolve the issues.
The Union minister complimented the industry representatives for this achievement towards attaining the vision of Prime Minister for self-reliance in critical drugs leading to ‘Atmanirbhar Bharat’.
The pharmaceutical sector in India, besides being a business venture is also a sector of social and strategic importance. He noted the pivotal role played by the pharmaceutical sector during C-19 times, not only domestically but also globally.
He appreciated the commitment of the sector to quality and affordability of drugs. The minister also encouraged the industry to invest in the area of research and innovation for sustainable global competitiveness by allocating adequate resources.
The minister of state, while complementing these industries, has requested to expedite the grounding of remaining projects and starting of the commercial productions.
The Project Management Agency of the Scheme, IFCI Limited, has presented the overview of the scheme and said that against the notified capacity of 44,000 MT of the eligible products, the Industries have committed the annual capacity of over 83,000MT.
Department officials also mentioned that a third round of applications are invited for the remaining 10 eligible products under the scheme, with the last date till March 13, 2022 and requested the Industries to apply to avail the benefits under the scheme.
The meeting was attended by the Secretary Pharmaceuticals and other officials of the Department.
The representatives from Centrient Pharmaceuticals India Pvt. Ltd., Meghmani LLP, Emmennar Pharma Pvt. Ltd., Andhra Organics Limited, Hetero Group, Sadhana Nitro Chem Ltd. and Sreepathi Pharmaceuticals Limited have attended the meeting and appreciated the scheme, launched by the government, in the thick of C-19 times.
Drug recall: Aurobindo, Sun Pharma recall these products
CDSCO gives nod to Sun Pharma to conduct Phase 4 clinical…
Drug recall: Medical Device – Infusion Pumps recalled due to this reason
How Antibiotics polluting Indian rivers: Study
Now, focus on e-consultation: Govt
Clinical trial of plant based drug for fatty liver soon: CDRI
DCGI announces classification for 133 Medical Devices in general hospital and…
USFDA gives nod to Zydus to market Dapagliflozin tablets
Latest Notifications regarding Pharmaceuticals
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
